These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 16773706)

  • 1. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
    Pusl T; Beuers U
    World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
    Beuers U
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
    Paumgartner G; Beuers U
    Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of cholestatic disease in 2017.
    de Vries E; Beuers U
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
    Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
    Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutical indications of ursodeoxycholic acid.
    Copaci I; Micu L; Iliescu L; Voiculescu M
    Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ursodeoxycholic acid: history and clinical implications].
    Beuers U; Trampert DC
    Ned Tijdschr Geneeskd; 2022 Sep; 166():. PubMed ID: 36300467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic cholestatic diseases.
    Poupon R; Chazouillères O; Poupon RE
    J Hepatol; 2000; 32(1 Suppl):129-40. PubMed ID: 10728800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
    Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
    Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
    Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U
    J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
    Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of ursodeoxycholic acid in patients with liver disease.
    Angulo P
    Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy of cholestatic liver diseases.
    Paumgartner G
    J Dig Dis; 2010 Jun; 11(3):119-25. PubMed ID: 20579215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Therapies for Chronic Cholestatic Liver Diseases.
    Wagner M; Fickert P
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favourable long term effect of ursodeoxycholic acid treatment on congenital vanishing bile duct syndromes.
    Karageorgos SA; Tzardi M; Stratakou S; Voumvouraki A; Notas G; Kouroumalis E
    Acta Gastroenterol Belg; 2018; 81(2):330-332. PubMed ID: 30024707
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
    Kotb MA
    Int J Mol Sci; 2012; 13(7):8882-8914. PubMed ID: 22942741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Smith T; Befeler AS
    Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
    Roma MG; Toledo FD; Boaglio AC; Basiglio CL; Crocenzi FA; Sánchez Pozzi EJ
    Clin Sci (Lond); 2011 Dec; 121(12):523-44. PubMed ID: 21854363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
    Linares Rodríguez A
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
    [No Abstract]   [Full Text] [Related]  

  • 20. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Rust C; Beuers U
    Clin Rev Allergy Immunol; 2005 Apr; 28(2):135-45. PubMed ID: 15879619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.